Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2023 (fiscal second quarter and first half of fiscal 2024). The filing is unaudited. Vistagen is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue.
Financial performance and position
| Metric | Three months ended September 30, 2023 | Six months ended September 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Sublicense revenue | $277,700 | $455,300 | $(892,500) and $(582,500), respectively |
| Research and development expense | $3.85 million | $8.05 million | $12.89 million and $28.19 million |
| General and administrative expense | $3.21 million | $6.19 million | $3.70 million and $8.49 million |
| Net loss | $(6.59) million | $(13.49) million | $(17.48) million and $(37.26) million |
| Basic and diluted loss per share | $(0.66) | $(1.55) | $(2.54) and $(5.41) |
- Cash and liquidity: Cash and cash equivalents were $37.6 million at September 30, up from $16.6 million at March 31, 2023. Current assets were $39.1 million and current liabilities $2.9 million. Management stated that cash on hand, together with the subsequent offering proceeds, was expected to fund planned operations for more than 12 months from issuance of the financial statements.
- Cash flow: Operating activities used $14.1 million in the six months, versus $32.3 million in the prior-year period. Financing activities provided $35.1 million, primarily from ATM share sales. There was no investing cash use in the period.
- Debt and obligations: The $879,500 insurance-premium note issued in May 2023 was repaid in August. No note payable remained at quarter-end. The company reported operating and financing lease obligations, but no material funded debt balance.
- Equity financing: ATM sales generated approximately $36.2 million net in the six months, including $35.1 million from 4.14 million shares sold in the September quarter. Stockholders’ equity was $35.6 million; accumulated deficit was $340.3 million.
- Profit margins are not meaningful for this pre-commercial company: revenue is limited to sublicensing, and the company reported operating and net losses.
Changes versus the prior comparable period
- First-half net loss narrowed to $13.5 million from $37.3 million, chiefly reflecting lower R&D expense as PALISADE-1 and PALISADE-2 activities wound down, as well as lower compensation and G&A costs.
- Second-quarter R&D expense fell to $3.9 million from $12.9 million; management attributed the decline principally to trial closeout and reduced development activity. Management expects R&D and G&A expenses to increase during the remainder of fiscal 2024 as the PALISADE program advances.
- Prior-year sublicense revenue was negative because Vistagen recorded a $892,500 cumulative catch-up adjustment after extending its estimated performance period under the AffaMed agreement. Current-period revenue was positive; this comparison does not represent product sales growth.
- Cash increased despite operating cash use, primarily because of ATM equity financing. Shares issued increased from 7.32 million at March 31 to 12.02 million at September 30, after retrospective adjustment for the June 2023 1-for-30 reverse split.
Outlook, programs, risks and notable items
- Funding outlook: On October 4, 2023, Vistagen closed a public offering of common shares and warrants and received approximately $93.5 million in net proceeds, subsequent to quarter-end. The financing extends the stated runway but creates potential dilution; exercise of the accompanying warrants could add further shares. The company states it will need substantial additional capital to develop and commercialize candidates, and future financing is not assured.
- Fasedienol: PALISADE-2 met its primary endpoint in 141 completed subjects: the between-group difference in mean SUDS change was −5.8 points (p=0.015). The study also reported positive secondary and exploratory responder results, and no serious adverse events. In contrast, PALISADE-1 did not meet its primary endpoint. PALISADE-3 was planned for the first half of 2024 and PALISADE-4 for the second half; a repeat-dose study was also planned for the second half of 2024. Subject to trial results and FDA feedback, management cited a potential NDA submission in the first half of 2026.
- Other candidates: Vistagen reported favorable safety and tolerability results from a U.S. Phase 1 study of itruvone and is considering potential Phase 2B development for major depressive disorder. It is preparing for U.S. IND-enabling work for PH80 and evaluating development paths for PH15 and PH284. These programs remain dependent on funding, study results and regulatory feedback.
- Partnering: A September 2023 exclusive negotiation agreement with Fuji Pharma covers a potential PH80 license for Japan. The $1.5 million payment was received in November 2023, after quarter-end, and is creditable against a fee if a definitive license is executed. Neither party is obligated to enter that agreement.
- Key risks: Clinical efficacy and regulatory approval remain uncertain, including the contrasting PALISADE-1 and PALISADE-2 results. Other disclosed risks include dependence on external manufacturers and clinical research organizations, potential trial delays or adverse safety findings, competition, intellectual-property protection, and the need for future financing. Vistagen also noted that COVID-related olfactory dysfunction could potentially affect pherine activity or study outcomes.
- Other items: The company reported no legal proceedings and no off-balance-sheet arrangements. Disclosure controls were assessed as effective. It reported an accumulated deficit and continuing losses, and noted that its prior-year auditor’s opinion included a going-concern qualification. The filing describes related-party consulting arrangements, including a transition consulting agreement with its former CFO.
Important facts for investors to verify
- Whether PALISADE-3 and PALISADE-4 started on schedule, their protocols and FDA feedback, and whether results support management’s potential NDA timeline.
- How the PALISADE-2 results compare with PALISADE-1, including trial size, endpoint analysis, and the implications of closing PALISADE-2 with 141 completed subjects.
- Post-offering cash, quarterly operating burn and updated runway assumptions, including planned trial costs and any further financing needs.
- The actual and potential dilution from the October offering’s common shares, pre-funded warrants, T1 warrants and T2 warrants, and subsequent share count.
- Whether Fuji Pharma and Vistagen execute a definitive PH80 license, and the timing and accounting for the $1.5 million payment.